Schulze-Bonhage A, Hirsch M, Knake S, Kaufmann E, Kegele J, Rademacher M, et al. Focal cortex stimulation with a novel implantable device and antiseizure outcomes in 2 prospective multicenter single-arm trials. JAMA Neurol. 2023;80(6):588–96.

Article  PubMed  PubMed Central  Google Scholar 

Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069–77.

Article  CAS  PubMed  Google Scholar 

Löscher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs. 2021;35(9):935–63.

Article  PubMed  PubMed Central  Google Scholar 

Nakamura M, Cho JH, Shin H, Jang IS. Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019;15(855):175–82.

Article  Google Scholar 

Perucca E, Bialer M, White HS. New GABA-targeting therapies for the treatment of seizures and epilepsy: I. role of GABA as a modulator of seizure activity and recently approved medications acting on the GABA system. CNS Drugs. 2023;37(9):755–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

French JA, Chung SS, Krauss GL, Lee SK, Maciejowski M, Rosenfeld WE, et al. Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study. Epilepsia. 2021;62(9):2142–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klein P, Aboumatar S, Brandt C, Dong F, Krauss GL, Mizne S, et al. Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2022;99(10):e989–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sperling MR, Klein P, Aboumatar S, Gelfand M, Halford JJ, Krauss GL, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099–108.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beltrán-Corbellini Á, Romeral-Jiménez M, Mayo P, Sánchez-Miranda Román I, Iruzubieta P, Chico-García JL, et al. Cenobamate in patients with highly refractory focal epilepsy: a retrospective real-world study. Seizure. 2023;111:71–7.

Article  PubMed  Google Scholar 

Villanueva V, Santos-Carrasco D, Cabezudo-García P, Gómez-Ibáñez A, Garcés M, Serrano-Castro P, et al. Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an Expanded Access Program. Epilepsia Open. 2023;8(3):918–29.

Article  PubMed  PubMed Central  Google Scholar 

Serrano-Castro PJ, Ramírez-García T, Cabezudo-Garcia P, Garcia-Martin G, De La Parra J. Effect of cenobamate on cognition in patients with drug-resistant epilepsy with focal onset seizures: an exploratory study. CNS Drugs. 2024;38(2):141–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):522–30.

Article  PubMed  Google Scholar 

Aboumatar S, Ferrari L, Stern S, Wade CT, Weingarten M, Connor GS, et al. Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: post-hoc analysis of a subset of patients from a phase 3, multicenter, open-label study. Epilepsy Res. 2024;200: 107306.

Article  CAS  PubMed  Google Scholar 

Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure. 2007;16(4):296–304.

Article  PubMed  Google Scholar 

Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol. 2004;3(10):618–21.

Article  CAS  PubMed  Google Scholar 

Weissinger F, Losch F, Winter Y, Brecht S, Lendemans D, Kockelmann E. Effectiveness of eslicarbazepine acetate in dependency of baseline anticonvulsant therapy: results from a German prospective multicenter clinical practice study. Epilepsy Behav. 2019;101(Pt A): 106574.

Article  PubMed  Google Scholar 

Privitera M, Richy FF, Schabert VF. Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures. Epilepsy Behav. 2022;126: 108429.

Article  PubMed  Google Scholar 

Sander JW, Rosenfeld WE, Halford JJ, Steinhoff BJ, Biton V, Toledo M. Long-term individual retention with cenobamate in adults with focal seizures: pooled data from the clinical development program. Epilepsia. 2022;63(1):139–49.

Article  CAS  PubMed  Google Scholar 

Kwok CS, Johnson EL, Krauss GL. Comparing safety and efficacy of “third-generation” antiepileptic drugs: long-term extension and post-marketing treatment. CNS Drugs. 2017;31(11):959–74.

Article  CAS  PubMed  Google Scholar 

Chung SS, Hogan RE, Blatt I, Lawson PB, Nguyen H, Clark AM, et al. Long-term safety and sustained efficacy of USL255 (topiramate extended-release capsules) in patients with refractory partial-onset seizures. Epilepsy Behav. 2016;59:13–20.

Article  PubMed  Google Scholar 

Krakow K, Walker M, Otoul C, Sander JW. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology. 2001;56(12):1772–4.

Article  CAS  PubMed  Google Scholar 

Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38–48.

Article  CAS  PubMed  Google Scholar 

Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Devinsky O, Hesdorffer DC, Thurman DJ, Lhatoo S, Richerson G. Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention. Lancet Neurol. 2016;15(10):1075–88.

Article  PubMed  Google Scholar 

Harden C, Tomson T, Gloss D, Buchhalter J, Cross JH, Donner E, et al. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsy Curr. 2017;17(3):180–7.

Article  PubMed  PubMed Central  Google Scholar 

de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav. 2008;12(4):540–6.

Article  PubMed  Google Scholar 

Gaitatzis A, Johnson AL, Chadwick DW, Shorvon SD, Sander JW. Life expectancy in people with newly diagnosed epilepsy. Brain. 2004;127(Pt 11):2427–32.

Article  PubMed  Google Scholar 

Winter Y, Daneshkhah N, Galland N, Kotulla I, Krüger A, Groppa S. Health-related quality of life in patients with poststroke epilepsy. Epilepsy Behav. 2018;80:303–6.

Article  PubMed  Google Scholar 

Winter Y, Uphaus T, Sandner K, Klimpe S, Stuckrad-Barre SV, Groppa S. Efficacy and safety of antiseizure medication in post-stroke epilepsy. Seizure. 2022;100:109–14.

Article  PubMed  Google Scholar 

Sinha N, Peternell N, Schroeder GM, de Tisi J, Vos SB, Winston GP, et al. Focal to bilateral tonic-clonic seizures are associated with widespread network abnormality in temporal lobe epilepsy. Epilepsia. 2021;62(3):729–41.

Article  CAS  PubMed  PubMed Central